In the paper by Hansson et al. (“Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF,” Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2020; 12:e12137. https://doi.org/10.1002/dad2.12137), an error occurred in the preparation of the paper for publication, requiring the following correction.
In the original publication, there was a phrasing error in the third paragraph of section 2.1 incorrectly stating that a commercially available assay was used to measure the CSF biomarker Aβ1‐40. This paragraph (beginning “CSF concentrations of Aβ1‐42…”) should be replaced with the following corrected text: “CSF concentrations of Aβ1‐42, P‐tau, and T‐tau were measured using the Conformité Européen approved Elecsys β‐Amyloid(1‐42) CSF, Elecsys Phospho‐Tau (181P) CSF, and Elecsys Total‐Tau CSF immunoassays on the cobas e 601 analyzer (Roche Diagnostics). For the measurement of Aβ1‐40, a robust prototype assay (for research use only) was used, which is not commercially available.”
The authors regret the error.